companies / aurontx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 13,400,00013.4M | ○ |
|---|---|---|
| founded | null | |
| hq | Newton, MA | |
| industry | unknown | |
| stage | null |
AI-driven AURIGIN drug-discovery platform with a lead candidate, AUTX-703, targeting cell-state plasticity. Develops therapies for AML, small-cell lung cancer, and neuroendocrine prostate cancer. Combines machine learning with biological insight to design small molecules in oncology and inflammation.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-12-18 | Funding round | 13,400,00013.4M | null | ○ |
Cloudflare, Google Font API, Google Hosted Libraries, Google Tag Manager, jquery 3.5.1
| fact | status | src |
|---|---|---|
| Funding round, $13.4M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $13.4M, 2024-12-18 → Funding round, $13.4M, 2024-12-18, ○ 2026-05-05 | latest_round | seed, $13.4M, 2024-12-18 → Funding round, $13.4M, 2024-12-18 | ○ 2026-05-05 |
Records begin 2026-09-24. all_changes